Together, the results suggest that adjunctive ZOL/IL2 administrations could significantly enhance and sustain enhance and sustain the Vγ2Vδ2 T-effector population producing anti-TB cytokines from week 3 through week 21, with some Vγ2Vδ2 T effector subpopulations trafficking to airway at weeks 3, 14, 19. Here, IL2 is linked to tuberculosis.